DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,528,360 | +4.7% | 195,600 | +1.3% | 0.22% | -3.9% |
| Q2 2023 | $46,362,480 | -4.3% | 193,177 | +0.5% | 0.23% | -6.9% |
| Q1 2023 | $48,467,544 | +55.7% | 192,301 | +63.9% | 0.24% | +8.4% |
| Q4 2022 | $31,138,013 | +46.4% | 117,316 | +42.4% | 0.23% | +76.6% |
| Q3 2022 | $21,275,000 | -5.9% | 82,369 | -7.6% | 0.13% | +16.4% |
| Q2 2022 | $22,603,000 | -78.5% | 89,159 | -75.1% | 0.11% | -61.9% |
| Q1 2022 | $105,156,000 | -65.9% | 358,492 | -61.7% | 0.29% | -43.9% |
| Q4 2021 | $308,041,000 | +22.1% | 936,265 | +13.0% | 0.52% | +3.0% |
| Q3 2021 | $252,191,000 | +32.4% | 828,376 | +16.7% | 0.50% | +16.0% |
| Q2 2021 | $190,509,000 | +35.5% | 709,900 | +13.6% | 0.43% | +4.1% |
| Q1 2021 | $140,637,000 | +16.9% | 624,830 | +15.4% | 0.41% | +2.7% |
| Q4 2020 | $120,267,000 | +52.4% | 541,400 | +47.8% | 0.40% | -0.2% |
| Q3 2020 | $78,897,000 | +107.8% | 366,400 | +70.7% | 0.40% | +61.0% |
| Q2 2020 | $37,965,000 | +206.5% | 214,700 | +139.9% | 0.25% | +26.1% |
| Q1 2020 | $12,388,000 | -76.1% | 89,500 | -73.5% | 0.20% | -28.7% |
| Q4 2019 | $51,738,000 | +36.4% | 337,100 | +28.3% | 0.28% | +7.3% |
| Q3 2019 | $37,944,000 | +61.0% | 262,711 | +59.3% | 0.26% | +52.9% |
| Q2 2019 | $23,564,000 | +64.4% | 164,873 | +51.8% | 0.17% | +29.8% |
| Q1 2019 | $14,337,000 | +103.0% | 108,600 | +58.5% | 0.13% | +50.6% |
| Q4 2018 | $7,064,000 | +20.8% | 68,500 | +27.3% | 0.09% | +29.9% |
| Q3 2018 | $5,849,000 | +180.8% | 53,824 | +155.0% | 0.07% | +109.4% |
| Q2 2018 | $2,083,000 | -66.7% | 21,104 | -71.6% | 0.03% | -81.2% |
| Q2 2017 | $6,260,000 | +42.0% | 74,183 | +43.9% | 0.17% | +54.5% |
| Q1 2017 | $4,408,000 | +1192.7% | 51,542 | +1071.4% | 0.11% | +900.0% |
| Q4 2016 | $341,000 | -82.9% | 4,400 | -82.7% | 0.01% | -75.0% |
| Q3 2016 | $1,991,000 | +147.6% | 25,400 | +193.1% | 0.04% | +109.5% |
| Q4 2015 | $804,000 | +58.0% | 8,667 | +29.2% | 0.02% | +250.0% |
| Q3 2014 | $509,000 | -60.5% | 6,709 | -59.0% | 0.01% | -64.7% |
| Q2 2014 | $1,288,000 | +233.7% | 16,366 | +227.3% | 0.02% | +325.0% |
| Q4 2013 | $386,000 | – | 5,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |